The challenges of Chagas disease - Grim outlook or glimmer of hope?

PLoS Medicine

Volumn 4, Issue 12, 2007, Pages 1852-1857

  Tarleton, Rick L ^a   Reithinger, Richard ^b,c,d   Urbina, Julio A ^e,f   Kitron, Uriel ^g   Gürtler, Ricardo E ^h  

^a UNIVERSITY OF GEORGIA   (United States)

^b Clinical Trials Area   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^f Drugs for Neglected Diseases Initiative   (Switzerland)

^g UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^h UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; INSECTICIDE; NIFURTIMOX; POSACONAZOLE; ANTIPARASITIC AGENT; PROTOZOAL VACCINE;

BLOOD DONOR; CHAGAS DISEASE; CLINICAL FEATURE; EUROPE; FOOD AND DRUG ADMINISTRATION; HEART CINEVENTRICULOGRAPHY; HUMAN; IMMIGRANT; ORGAN DONOR; POVERTY; REVIEW; SCREENING TEST; SOUTH AND CENTRAL AMERICA; THORAX RADIOGRAPHY; TRIATOMA INFESTANS; TRYPANOSOMA CRUZI; UNITED STATES; VECTOR CONTROL; WORK DISABILITY; ANIMAL; ARTICLE; DISEASE CARRIER; DISEASE TRANSMISSION; DRUG MANUFACTURE; IMMUNOLOGY; INFECTION CONTROL; PATHOGENICITY; RARE DISEASE; SOUTH AMERICA;

ANIMALS; ANTIPARASITIC AGENTS; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; COMMUNICABLE DISEASE CONTROL; DISEASE VECTORS; HUMANS; ORPHAN DRUG PRODUCTION; PROTOZOAN VACCINES; RARE DISEASES; SOUTH AMERICA; TRYPANOSOMA CRUZI;

EID: 38049079910     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040332     Document Type: Review

References (43)

1. World Health Organization (2004) The World Health Organization report 2004. Changing history. Available: http://www.who.int/whr/2004/en/. Accessed 19 November 2007.
2. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, et al. (2006) Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 3: e102. doi:10.1371/journal.pmed.0030102
3. Centers for Disease Control and Prevention (2007) Blood donor screening for chagas disease - United States, 2006-2007. MMWR Morb Mortal Wkly Rep 56: 141-143.
4. Riera C, Guarro A, Kassab HE, Jorba JM, Castro M, et al. (2006) Congenital transmission of Trypanosoma cruzi in Europe (Spain): A case report. Am J Trop Med Hyg 75: 1078-1081.
5. Food and Drug Administration (2006) Product approval information licensing action. ORTHO T. cruzi ELISA Test System. Available: http://www.fda.gov/cber/products/tryorth121306.htm. Accessed 19 November 2007.
6. Beard CB, Pye G, Steurer FJ, Rodriguez R, Campman R, et al. (2003) Chagas disease in a domestic transmission cycle, southern Texas, USA. Emerg Infect Dis 9:103-105.
7. Dorn P, Perniciaro L, Yabsley MJ, Roellig DM, Balsamo G, et al. (2007) Autochthonous transmission of Trypanosoma cruzi, Louisiana. Emerg Infect Dis 13: 605-507.
8. [No authors listed] (2006) Chagas' disease - An epidemic that can no longer be ignored. Lancet 368: 619.
9. Maguire JH (2006) Chagas' disease - Can we stop the deaths? N Engl J Med 355: 760-761.
10. Schofield CJ, Jannin J, Salvatella R (2006) The future of Chagas disease control. Trends Parasitol 22: 583-588.
11. Gürtler RE, Segura EL, Cohen JE (2003) Congenital transmission of Trypanosoma cruzi infection in Argentina. Emerg Infect Dis 9: 29-32.
12. Young C, Losikoff P, Chawla A, Glasser L, Forman E (2007) Transfusion-acquired Trypanosoma cruzi infection. Transfusion 47: 540-547.
13. Centers for Disease Control and Prevention (2006) Chagas disease after organ transplantation - Los Angeles, California, 2006. MMWR Morb Mortal Wkly Rep 55: 798-800.
14. Benchimol Barbosa PR (2006) The oral transmission of Chagas' disease: An acute form of infection responsible for regional outbreaks. Int J Cardiol 112:132-133.
15. Prata A (2001) Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100.
16. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, et al. (2006) Development and validation of a risk score for predicting death in Chagas'heart disease. N Engl J Med 355: 799-808.
17. Dias JC, Silveira AC, Schofield CJ (2002) The impact of Chagas disease control in Latin America: A review. Mem Inst Oswaldo Cruz 97: 603-612.
18. Picollo M, Vassena C, Santo Orihuela P, Barrios S, Zaidemberg M, et al. (2005) High resistance to pyrethroid insecticides associated with ineffective field treatments in Triatoma infestans (Hemiptera: Reduviidae) from Northern Argentina. J Med Entomol 42: 637-642.
19. Briceno-Leon R (1987) Rural housing for control of Chagas disease in Venezuela. Parasitol Today 3: 384-387.
20. Urbina JA, Docampo R (2003) Specific chemotherapy of Chagas disease: Controversies and advances. Trends Parasitol 19: 495-501.
21. Viotti R, Vigliano C, Lococo B, Armenti H, LaPuente A, et al. (1998) Chronic chagasic cardiomyopathy: Clinical and serologic evolution with and without benznidazole in long-term follow-up. XIII World Congress of Cardiology; 26-30 April 1998; Rio de Janeiro, Brazil. pp. 697-701.
22. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, et al. (2006) Longterm cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: A nonrandomized trial. Ann Intern Med 144: 724-734.
23. Andrade AL, Martelli CM, Oliveira RM, Silva SA, Aires AI, et al. (2004) Short report: Benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg 71: 594-597.
24. Pereira-Chioccola VL, Fragata-Filho AA, Levy AM, Rodrigues MM, Schenkman S (2003) Enzyme-linked immunoassay using recombinant transsialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment. Clin Diagn Lab Immunol 10: 826-830.
25. de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, et al. (1996) Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348: 1407-1413.
26. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, et al. (1998) Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 59: 526-529.
27. Sosa-Estani S, Segura EL (2006) Etiological treatment in patients infected by Trypanosoma cruzi: Experiences in Argentina. Curr Opin Infect Dis 19: 583-587.
28. de Castro AM, Luquetti AO, Rassi A, Chiari E, Galvao LM (2006) Detection of parasitemia profiles by blood culture after treatment of chronic Trypanosoma cruzi infection. Parasitol. Res 99: 379-383.
29. Moran M, Ropars AL, Guzman J, Diaz J, Garrison C (2005) The new landscape of neglected disease drug development. The Wellcome Trust. Available: http://www.thegeorgeinstitute.org/shadomx/apps/fms/fmsdownload.cfm?file_uuid= F2B06396-EEA0-851E-3049-C9A030AEDE0F&siteName=iih. Accessed 19 November 2007.
30. Tarleton RL (2001) Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 31: 549-553.
31. Pirard M, Iihoshi N, Boelaert M, Basanta P, Lopez F, et al. (2005) The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion 45: 554-561.
32. Caballero ZC, Sousa OE, Marques WP, Saez-Alquezar A, Umezawa ES (2007) Evaluation of serological tests to identify human Trypanosoma cruzi infection and cross-reactivity with Trypanosoma rangeli and Leishmania spp cases. Clin Vaccine Immunol 14: 1045-1049.
33. Silveira-Lacerda EP, Silva AG, Junior SF, Souza MA, Kesper N, et al. (2004) Chagas' disease: Application of TESA-blot in inconclusive sera from a Brazilian blood bank. Vox Sang 87: 204-207.
34. Wincker P, Bosseno MF, Britto C, Yaksic N, Cardoso MA, et al. (1994) High correlation between Chagas' disease serology and PCR-based detection of Trypanosoma cruzi kinetoplast DNA in Bolivian children living in an endemic area. FEMS Microbiol Lett 124: 419-423.
35. Salomone OA, Basquiera AL, Sembaj A, Aguerri AM, Reyes ME, et al. (2003) Trypanosoma cruzi in persons without serologic evidence of disease, Argentina. Emerg Infect Dis 9: 1558-1562.
36. Gutierrez R, Angulo VM, Tarazona Z, Britto C, Fernandes O (2004) Comparison of four serological tests for the diagnosis of Chagas disease in a Colombian endemic area. Parasitology 129: 439-444.
37. Gürtler RE, Canale DM, Spillmann C, Stariolo R, Salomon OD, et al. (2004) Effectiveness of residual spraying with deltamethrin and permethrin on peridomestic populations of Triatoma infestans in rural western Argentina: A district-wide randomized trial. Bull World Health Organ 82: 196-205.
38. Cohen JE, Gürtler RE (2001) Modeling household transmission of American trypanosomiasis. Science 293: 694-698.
39. Cecere MC, Vazquez-Prokopec GM, Gürtler RE, Kitron U (2006) Reinfestation sources for Chagas disease vector, Triatoma infestans, Argentina. Emerg Infect Dis 12: 1096-1102.
40. Kroeger A, Villegas E, Ordonez-Gonzalez J, Pabon E, Scorza JV (2003) Prevention of the transmission of Chagas' disease with pyrethroid-impregnated materials. Am J Trop Med Hyg 68: 307-311.
41. Reithinger R, Ceballos L, Stariolo R, Davies CR, Gürtler RE (2006) Extinction of experimental Triatoma infestans populations following continuous exposure to dogs wearing deltamethrin-treated collars. Am J Trop Med Hyg 74: 766-771.
42. Atwood JA 3rd, Weatherly DB, Minning TA, Bundy B, Cavola C, et al. (2005) The Trypanosoma cruzi proteome. Science 309: 473-476.
43. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, et al. (2005) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309: 409-415.